

**IN THE CLAIMS:**

*This listing of claims will replace all prior versions, and listings, of claims in the application.*

Claims 1-25 (Canceled)

Claim 26. (Currently amended) Process for screening compounds that bind to a receptor of the ED<sub>b</sub>-fibronectin domains, whereby the process comprises:

comparison of a response of cells in the presence of one or more of these compounds with the control response of said cells in the absence of these compounds, whereby the cells express a protein according to claim 1 [one of claims 1-10] or

comprise a nucleic acid that codes for this protein, and whereby the response or the control response is mediated by a receptor of the ED<sub>b</sub>-fibronectin domains.

Claim 27. (Original) Process according to claim 26, whereby the response or control response comprises the adherence of cells to surfaces that are coated with the ED<sub>b</sub>-fibronectin domains or portions thereof.

Claim 28. (Currently amended) Process according to claim 26 [one of claims 26-27], wherein a binding region of the ED<sub>b</sub>-fibronectin domains comprises sequences SEQ ID NOS: 1-4 or portions thereof.

Claim 29. (Original) Process according to claim 26, wherein the response or the control response comprises the proliferation of cells on surfaces that are coated with the ED<sub>b</sub>-fibronectin domains or portions thereof.

Claim 30. (Original) Process according to claim 26, wherein the response or the control response comprises the proliferation, migration and differentiation of endothelial cells in a collagen matrix that is mixed with the ED<sub>b</sub>-fibronectin domains or portions thereof.

•  
-  
•

Claim 31. (Currently amended) Process according to claim 26 [one of claims 26-30], whereby the compounds are selected from the group that comprises antibodies, artificial antibodies, antibody fragments, peptides, low-molecular compounds, aptamers and Spiegelmers.

Claim 32. (Original) Process according to claim 31, wherein the antibodies are recombinant antibodies.

Claim 33. (Original) Process according to claim 31, wherein the antibodies are selected from the group that comprises scFv and fragments thereof.

Claim 34 - 55 (Canceled)